We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Clinical Value of the PD-1/PD-L1/PD-L2 Pathway in Patients Suffering from Endometriosis.
- Authors
Suszczyk, Dorota; Skiba, Wiktoria; Zardzewiały, Witold; Pawłowska, Anna; Włodarczyk, Karolina; Polak, Grzegorz; Tarkowski, Rafał; Wertel, Iwona
- Abstract
The interaction between dendritic cells (DCs) and T cells mediated by the programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1)/programmed cell death ligand 2 (PD-L2) pathway is the most important point in regulating immunological tolerance and autoimmunity. Disturbances in the quantity, maturity, and activity of DCs may be involved in the implantation and growth of endometrial tissue outside the uterus in endometriosis (EMS). However, little is known about the role of the immune checkpoint pathways in EMS. In our study, we examined the expression of PD-L1/PD-L2 on myeloid DCs (mDCs) and plasmacytoid DCs (pDCs) in the peripheral blood (PB) and peritoneal fluid (PF) of both EMS patients (n = 72) and healthy subjects (n = 20) via flow cytometry. The concentration of soluble PD-L1 and PD-L2 in the plasma and PF of EMS patients and the control group were determined using ELISA. We demonstrated an elevated percentage of mDCs, mDCs and pDCs with the PD-L1or PD-L2 expression, and a higher concentration of the soluble forms of PD-L1 and PD-L2 in the PF than in the plasma of EMS patients. We conclude that the peritoneal cavity environment and the PD-1/PD-L1/PD-L2 axis may play an important role in the modulation of immune response and the development and/or progression of EMS.
- Subjects
ENDOMETRIOSIS; PROGRAMMED cell death 1 receptors; IMMUNE checkpoint proteins; PERITONEUM; IMMUNOLOGICAL tolerance; ASCITIC fluids; CELL death; ENDOMETRIUM
- Publication
International Journal of Molecular Sciences, 2022, Vol 23, Issue 19, p11607
- ISSN
1661-6596
- Publication type
Article
- DOI
10.3390/ijms231911607